GCP
SLDB icon

GSA Capital Partners’s Solid Biosciences SLDB Stock Holding History

GSA Capital Partners’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-29,569
Closed -$213K – 2137
2026
Q1 		$213K Buy
+29,569
New +$190K 0.01% 1429
2022
Q1 		– Sell
-7,540
Closed -$198K – 1797
2021
Q4 		$198K Buy
7,540
+833
+12% +$25.5K 0.02% 1235
2021
Q3 		$240K Buy
+6,707
New +$285K 0.02% 1146
2020
Q4 		– Sell
-877
Closed -$27K – 1561
2020
Q3 		$27K Buy
877
+182
+26% +$6.97K ﹤0.01% 1209
2020
Q2 		$31K Sell
695
-639
-48% -$26.5K 0.02% 551
2020
Q1 		$48K Buy
+1,334
New +$66K 0.01% 961
2019
Q2 		– Sell
-831
Closed -$115K – 1707
2019
Q1 		$115K Buy
+831
New +$208K 0.01% 1321

Other funds holding SLDB

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GSA Capital Partners's SLDB Position: Q2 2026 in Review

GSA Capital Partners sold out of Solid Biosciences (SLDB) in Q2 2026, closing a stake of 29,569 shares — an estimated $213K sold.

GSA Capital Partners first reported a position in SLDB in Q1 2019 and held it in 7 quarters. The position peaked at $240K in Q3 2021. 157 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

  • GSA Capital Partners reported no remaining Solid Biosciences position as of Q2 2026 after selling out during the quarter.
  • GSA Capital Partners sold 29,569 Solid Biosciences shares in Q2 2026, an estimated $213K.
  • GSA Capital Partners first reported a position in Solid Biosciences in Q1 2019 and held it in 7 quarters.
  • GSA Capital Partners's Solid Biosciences position peaked at $240K in Q3 2021.
  • 157 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.